Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial

Suissa, 2012, Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality, Thorax, 67, 957, 10.1136/thoraxjnl-2011-201518 Soler-Cataluna, 2005, Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease, Thorax, 60, 925, 10.1136/thx.2005.040527 Seemungal, 1998, Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 157, 1418, 10.1164/ajrccm.157.5.9709032 Donaldson, 2002, Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease, Thorax, 57, 847, 10.1136/thorax.57.10.847 Kanoh, 2010, Mechanisms of action and clinical application of macrolides as immunomodulatory medications, Clin Microbiol Rev, 23, 590, 10.1128/CMR.00078-09 Albert, 2011, Azithromycin for prevention of exacerbations of COPD, N Engl J Med, 365, 689, 10.1056/NEJMoa1104623 Serisier, 2013, Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases, Lancet Respir Med, 1, 262, 10.1016/S2213-2600(13)70038-9 Wenzel, 2012, Antibiotic prevention of acute exacerbations of COPD, N Engl J Med, 367, 340, 10.1056/NEJMct1115170 Uzun, 2012, Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial, Trials, 13, 82, 10.1186/1745-6215-13-82 Rabe, 2007, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, Am J Respir Crit Care Med, 176, 532, 10.1164/rccm.200703-456SO Isenberg, 2004 Anthonisen, 1987, Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease, Ann Intern Med, 106, 196, 10.7326/0003-4819-106-2-196 Seemungal, 2008, Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations, Am J Respir Crit Care Med, 178, 1139, 10.1164/rccm.200801-145OC Banerjee, 2005, The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD, Respir Med, 99, 208, 10.1016/j.rmed.2004.06.009 He, 2010, Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease, Respiration, 80, 445, 10.1159/000321374 Blasi, 2010, Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy, Pulm Pharmacol Ther, 23, 200, 10.1016/j.pupt.2009.12.002 Suzuki, 2001, Erythromycin and common cold in COPD, Chest, 120, 730, 10.1378/chest.120.3.730 Clement, 2006, Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial, Thorax, 61, 895, 10.1136/thx.2005.057950 Saiman, 2003, Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial, JAMA, 290, 1749, 10.1001/jama.290.13.1749 Miravitlles, 2004, Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study, Thorax, 59, 387, 10.1136/thx.2003.008730 Malhotra-Kumar, 2007, Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study, Lancet, 369, 482, 10.1016/S0140-6736(07)60235-9 Hahn, 2011, Azithromycin for prevention of exacerbations of COPD, N Engl J Med, 365, 2236 Wong, 2012, Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial, Lancet, 380, 660, 10.1016/S0140-6736(12)60953-2 Altenburg, 2013, Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial, JAMA, 309, 1251, 10.1001/jama.2013.1937 Serisier, 2013, Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial, JAMA, 309, 1260, 10.1001/jama.2013.2290 Martinez-Garcia, 2011, Factors associated with bronchiectasis in patients with COPD, Chest, 140, 1130, 10.1378/chest.10-1758 Donaldson, 2013, Factors associated with change in exacerbation frequency in COPD, Respir Res, 14, 79, 10.1186/1465-9921-14-79 Hurst, 2010, Susceptibility to exacerbation in chronic obstructive pulmonary disease, N Engl J Med, 363, 1128, 10.1056/NEJMoa0909883 Beeh, 2013, Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial, Respir Res, 14, 116, 10.1186/1465-9921-14-116 Suzuki, 2002, Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells, Am J Respir Crit Care Med, 165, 1113, 10.1164/ajrccm.165.8.2103094 Marjanovic, 2011, Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro, Pharmacol Res, 63, 389, 10.1016/j.phrs.2011.02.001 Hodge, 2008, Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 178, 139, 10.1164/rccm.200711-1666OC Halldorsson, 2010, Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection, Am J Respir Cell Mol Biol, 42, 62, 10.1165/rcmb.2008-0357OC Marin, 2012, Effect of bronchial colonisation on airway and systemic inflammation in stable COPD, COPD, 9, 121, 10.3109/15412555.2011.636407 Nahata, 1996, Drug interactions with azithromycin and the macrolides: an overview, J Antimicrob Chemother, 37, 133, 10.1093/jac/37.suppl_C.133 Brusselle, 2013, Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial, Thorax, 68, 322, 10.1136/thoraxjnl-2012-202698